MedTrace Logo

Maintenance Treatment With Capecitabine Versus Observation in Breast Cancer Patients

NCT00130533 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 876

Last updated 2023-03-31

Study results available
· View outcomes & findings →

Summary

This is a prospective, open-label, randomized phase III study assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer.

Conditions

Interventions

DRUG

Capecitabine

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • IBEROAMERICAN COALITION FOR BREAST ONCOLOGY RESEARCH (CIBOMA)

    collaborator UNKNOWN

  • Spanish Breast Cancer Research Group

    lead OTHER

Principal Investigators

  • Study Principal Investigator · Hospital Clínico Universitario de Valencia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2017-02-17
Completion
2017-02-17

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00130533 on ClinicalTrials.gov